Stanford University
Showing 41-50 of 92 Results
-
Kamyar (Kam) Firouzi
Affiliate, Ginzton, E.L. Laboratory
BioDr. Kamyar (Kam) Firouzi’s work centers on developing next-generation neural interfaces that unite decoding, modeling, and modulation of brain activity. His research integrates focused ultrasound (FUS) neuromodulation, blood–brain-barrier (BBB) opening, and microchip-based sensing (CMUT/ASIC) with AI-driven neural decoding and generative modeling to build adaptive communication systems between the brain and machines. At Stanford, he focuses on translating cutting-edge neurotechnology research into clinical and commercial applications, advancing experimental platforms into scalable systems for cognitive restoration, neurorehabilitation, and human–computer symbiosis.
Dr. Firouzi co-founded and led Althea, a pioneering agentic AI company that redefined human–computer interaction in healthcare. Althea developed proprietary multimodal language models and voice-based agentic systems that enable computers to reason, speak, and act, augmenting clinical teams and patient engagement. Through Althea, he demonstrated how agentic AI can serve as a powerful layer of human–AI interface, extending intelligence and decision support across complex healthcare systems. Earlier in his career, Dr. Firouzi co-founded Liminal Sciences, a neurotechnology company that introduced acousto-encephalography (AEG), the first noninvasive method for real-time monitoring of cerebral blood flow and pressure, later merged with Hyperfine (NASDAQ: HYPR).
Across his academic and entrepreneurial work, Dr. Firouzi continues to explore how neural decoding, AI architectures, and high-performance computing can be unified to advance precision neuromodulation, brain–AI interfaces, and the next era of intelligent human augmentation. -
Michael Fischbach
Liu (Liao) Family Professor
Current Research and Scholarly InterestsThe microbiome carries out extraordinary feats of biology: it produces hundreds of molecules, many of which impact host physiology; modulates immune function potently and specifically; self-organizes biogeographically; and exhibits profound stability in the face of perturbations. Our lab studies the mechanisms of microbiome-host interactions. Our approach is based on two technologies we recently developed: a complex (119-member) defined gut community that serves as an analytically manageable but biologically relevant system for experimentation, and new genetic systems for common species from the microbiome. Using these systems, we investigate mechanisms at the community level and the strain level.
1) Community-level mechanisms. A typical gut microbiome consists of 200-250 bacterial species that span >6 orders of magnitude in relative abundance. As a system, these bacteria carry out extraordinary feats of metabolite consumption and production, elicit a variety of specific immune cell populations, self-organize geographically and metabolically, and exhibit profound resilience against a wide range of perturbations. Yet remarkably little is known about how the community functions as a system. We are exploring this by asking two broad questions: How do groups of organisms work together to influence immune function? What are the mechanisms that govern metabolism and ecology at the 100+ strain scale? Our goal is to learn rules that will enable us to design communities that solve specific therapeutic problems.
2) Strain-level mechanisms. Even though gut and skin colonists live in communities, individual strains can have an extraordinary impact on host biology. We focus on two broad (and partially overlapping) categories:
Immune modulation: Can we redirect colonist-specific T cells against an antigen of interest by expressing it on the surface of a bacterium? How do skin colonists induce high levels of Staphylococcus-specific antibodies in mice and humans?
Abundant microbiome-derived molecules: By constructing single-strain/single-gene knockouts in a complex defined community, we will ask: What are the effects of bacterially produced molecules on host metabolism and immunology? Can the molecular output of low-abundance organisms impact host physiology?
3) Cell and gene therapy. We have begun two new efforts in mammalian cell and gene therapies. First, we are developing methods that enable cell-type specific delivery of genome editing payloads in vivo. We are especially interested in delivery vehicles that are customizable and easy to manufacture. Second, we have begun a comprehensive genome mining effort with an emphasis on understudied or entirely novel enzyme systems with utility in mammalian genome editing. -
Martin Fischer
Kumagai Professor in the School of Engineering and Senior Fellow at the Precourt Institute for Energy
BioProfessor Fischer's research goals are to improve the productivity of project teams involved in designing, building, and operating facilities and to enhance the sustainability of the built environment. His work develops the theoretical foundations and applications for virtual design and construction (VDC). VDC methods support the design of a facility and its delivery process and help reduce the costs and maximize the value over its lifecycle. His research has been used by many small and large industrial government organizations around the world.
-
Daniel Fisher
Marjorie Mhoon Fair Professor
Current Research and Scholarly InterestsEvolutionary & ecological dynamics & diversity, microbial, expt'l, & cancer
-
Ian Fisher
Humanities and Sciences Professor, Professor of Applied Physics and, by courtesy, of Materials Science and Engineering
Current Research and Scholarly InterestsOur research focuses on the study of quantum materials with unconventional magnetic & electronic ground states & phase transitions. Emphasis on design and discovery of new materials. Recent focus on use of strain as a probe of, and tuning parameter for, a variety of electronic states. Interests include unconventional superconductivity, quantum phase transitions, nematicity, multipolar order, instabilities of low-dimensional materials and quantum magnetism.
-
Paul Graham Fisher, MD
Beirne Family Professor of Pediatric Neuro-Oncology, Professor of Pediatrics and, by courtesy, of Neurosurgery and of Epidemiology and Population Health
Current Research and Scholarly InterestsClinical neuro-oncology: My research explores the epidemiology, natural history, and disease patterns of brain tumors and other cancers in childhood, as well as prospective clinical trials for treating these neoplasms. Research interests also include neurologic effects of cancer and its therapies.
-
Philip Andrew Fisher
Diana Chen Professor of Early Childhood Learning and Professor, by courtesy, of Pediatrics
BioDr. Philip Fisher is the Diana Chen Professor of Early Childhood Learning in the Graduate School of Education and the Director of the Stanford Center on Early Childhood. His research, focuses on developing and evaluating scalable early childhood interventions in communities, and on translating scientific knowledge regarding healthy development under conditions of adversity for use in social policy and programs. He is particularly interested in the effects of early stressful experiences on children's development, and in prevention and treatment programs for improving children's functioning in areas such as relationships with caregivers and peers, social-emotional development, and academic achievement. He is currently the lead investigator in the ongoing RAPID-EC project, a national survey on the well-being of households with young children during the COVID-19 pandemic. Dr. Fisher is the developer of a number of widely implemented evidence-based interventions for supporting healthy child development in the context of social and economic adversity, including Treatment Foster Care Oregon for Preschoolers (TFCO-P) and Kids in Transition to School (KITS). Most recently, he developed the Filming Interactions to Nurture Development (FIND) video coaching program for supporting parenting in the home environment and early childhood care and education professionals in childcare and preschool contexts. He has published over 250 scientific papers in peer reviewed journals. He is the recipient of the 2012 Society for Prevention Research Translational Science Award, and a 2019 Fellow of the American Psychological Society.
-
Robert Fisher, MD, PhD
The Maslah Saul, MD, Professor and Professor, by courtesy, of Neurosurgery
Current Research and Scholarly InterestsDr. Fisher is interested in clincal, laboratory and translational aspects of epilepsy research. Prior work has included: electrical deep brain stimulation for epilepsy, studied in laboratory models and clinical trials; drug delivery to a seizure focus; mechanisms of absence epilepsy studied with in vitro slices of brain thalamus; hyperthermic seizures; diagnosis and treatment of non-epileptic seizures, the post-ictal state; driving and epilepsy; new antiepileptic drugs; surgery for epilepsy.
-
James Fishkin
Janet M. Peck Professor of International Communication, Senior Fellow at the Freeman Spogli Institute for International Studies and Professor, by courtesy, of Political Science
BioJames S. Fishkin holds the Janet M. Peck Chair in International Communication at Stanford University where he is Professor of Communication, Professor of Political Science (by courtesy) and Director of the Deliberative Democracy Lab.
He received his B.A. from Yale in 1970 and holds a Ph.D. in Political Science from Yale as well as a second Ph.D. in Philosophy from Cambridge.
He is the author of Democracy When the People Are Thinking (Oxford 2018), When the People Speak (Oxford 2009), Deliberation Day (Yale 2004 with Bruce Ackerman) and Democracy and Deliberation (Yale 1991).
He is best known for developing Deliberative Polling® – a practice of public consultation that employs random samples of the citizenry to explore how opinions would change if they were more informed. His work on deliberative democracy has stimulated more than 100 Deliberative Polls in 28 countries around the world. It has been used to help governments and policy makers make important decisions in Texas, China, Mongolia, Japan, Macau, South Korea, Bulgaria, Brazil, Uganda and other countries around the world.
He is a Fellow of the American Academy of Arts and Sciences, a Guggenheim Fellow, a Fellow of the Center for Advanced Study in the Behavioral Sciences at Stanford, and a Visiting Fellow Commoner at Trinity College, Cambridge.
